Premium
Studies of the uricosuric action of the hypolipidemic drug halofenate
Author(s) -
Ravenscroft Peter J.,
Sands John M.,
Emmerson Bryan T.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973144part1547
Subject(s) - uricosuric , hypertriglyceridemia , medicine , drug , triglyceride , uric acid , endocrinology , hyperlipidemia , gout , pharmacology , cholesterol , chemistry , hyperuricemia , diabetes mellitus
Six hyperuricemic patients, with a high incidence of hypertriglyceridemia, were placed on a purine‐free maintenance diet during a 2 week single‐blind study of the uricosuric activity of halofenate (MK‐185). In a single dose‐response study, halofenate, given in a dose of 1 gm orally, produced a uricosuric effect of 48 hours' duration and a peak response 6 to 8 hours after administration, with a significant fall in serum urate. In a 3 day trial of the drug, a progressive increase in urate excretion occurred with a further fall in serum urate. During the study, the mean triglyceride concentration fell by 26% and cholesterol by 15% of the pretreatment values.